BioSpace News Archive

Canine Companions for Independence, the nation’s first and largest assistance dog organization, will honor James Schenck, PenFed Credit Union President and CEO and PenFed Foundation CEO at its 16th Annual Hearts & Heroes Gala on June 13 in New York City.

The latest results from a collaboration between Cigna and Santa Clara County IPA (SCCIPA) show that the program continues to drive better health care quality for nearly 18,000 Silicon Valley residents while achieving significantly better affordability.

Vibalogics GmbH, a contract development and manufacturing organization (CDMO) focused on complex live biological products, is being acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.

Medical Group Management Association (MGMA) released its annual Provider Compensation and Production Report, the most comprehensive view of provider compensation in the United States, representing data from more than 147,000 physicians and non-physician providers in over 5,500 organizations

The National Institute of Mental Health (NIMH) has awarded a $13.5 million grant to a team of McLean Hospital investigators to support their research into stress chemicals and circuits in the brain.

Today, Sarah Cannon announced that it will present its latest cancer research insights through more than 100 abstracts and presentations at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting hosted in Chicago, from May 31-June 4, 2019.

Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that the Food and Drug Administration has recently granted mAb114, an experimental treatment for Ebola, Orphan Drug Designation.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present company overviews at the following conferences

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Indivior PLC from March 10, 2015 through April 9, 2019, inclusive (the “Class Period”) of the important June 24, 2019 lead plaintiff deadline in the securities class action filed by the firm

IQVIA™ (NYSE:IQV) is pleased to have provided support towards the approval from the U.S. Food and Drug Administration to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include the treatment of men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer